Compare Natera Inc. Common Stock (NTRA) vs Toronto-Dominion Bank (TD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Toronto-Dominion Bank — how do they compare? Natera Inc. Common Stock trades at $394.6 (market cap $57.03B), while Toronto-Dominion Bank trades at $117.63 (market cap $191.91B). The key difference: Toronto-Dominion Bank is far larger — about 3.4× Natera Inc. Common Stock's market cap, and Toronto-Dominion Bank pays a 2.66% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Toronto-Dominion Bank for 85 Days on average.
| NTRA | TD | |
|---|---|---|
Market Cap | $57.03B | $191.91B |
Volume | 1,131,157 | 1,115,140 |
Sector | Health | Financials |
52-Week High | $425.64 | $124.80 |
52-Week Low | $179.42 | $78.72 |
Typical Hold Time | 0 Days | 85 Days |
Enterprise Value | $56.18B | $568.32B |
Dividend Yield | — | 2.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
TD (Toronto-Dominion Bank) trades at $117.63, up 0.98% today, with a bearish technical signal but strong fundamentals including a P/E of 18.01 and net income margin of 24.88%. Recent earnings have consistently beaten estimates, and the company announced a $10 billion share buyback program (Proactive Investors, 2026-09-30). Cash flow trends show volatility, with 2025 net cash flow at $1.08 billion. The stock faces headwinds from a high debt-to-asset ratio of 20.86 in 2025, though analyst consensus is bullish with 52.94% buy ratings.
The outlook for TD is mixed: solid profitability and shareholder returns via buybacks and dividends support upside, but technical weakness and elevated debt pose risks. Investors should weigh strong earnings momentum against macroeconomic sensitivity and regulatory scrutiny from ongoing anti-money laundering remediation. The stock's valuation appears reasonable relative to peers, but market sentiment remains cautious due to cash flow inconsistencies.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Toronto-Dominion Bank
Toronto-Dominion is one of Canada's two largest banks and operates three business segments: Canadian retail banking, U.S. retail banking, and wholesale banking. The bank's U.S. operations span from Maine to Florida, with a strong presence in the Northeast. It also has a 13% ownership stake in Charles Schwab.
Read more on TD →
